Baseline characteristics of the study patients
| . | Total (N = 3032) . |
|---|---|
| Age, y* | 61.8 ± 12.2 |
| >70 y, no. (%) | 795 (26.2) |
| Female, no. (%) | 1751 (57.8) |
| Body-mass index, kg/m2* | 24.7 ± 5.0 |
| ≤18 kg/m2, no. (%) | 128 (4.2) |
| ≥30 kg/m2, no. (%) | 405 (13.4) |
| Eastern Cooperative Oncology Group performance status, no. (%)† | |
| 0 | 1642 (58.1) |
| 1 | 930 (32.9) |
| 2 | 227 (8.0) |
| 3 | 28 (1.0) |
| 4 or 5 | 0 (0.0) |
| Medical history, no. (%)‡ | |
| Previous thromboembolism | 448 (14.8) |
| Pulmonary embolism | 42 (1.4) |
| Deep-vein thrombosis | 129 (4.3) |
| Superficial-vein thrombosis | 54 (1.8) |
| Myocardial infarction | 104 (3.4) |
| Acute lower-limb ischemia | 114 (3.8) |
| Stroke or transient ischemic attack | 81 (2.7) |
| Previous implanted port | 231 (7.6) |
| Diabetes | 346 (11.4) |
| Ongoing medications at the time of inclusion | |
| Immunosuppressive therapy | 19 (0.6) |
| Corticosteroids | 161 (5.3) |
| Statins | 515 (17.0) |
| Erythropoietin | 13 (0.4) |
| Hormone therapy§ | 57 (1.9) |
| Anticoagulant agents at prophylactic dose|| | 247 (8.1) |
| Antiplatelet agents | 458 (15.1) |
| . | Total (N = 3032) . |
|---|---|
| Age, y* | 61.8 ± 12.2 |
| >70 y, no. (%) | 795 (26.2) |
| Female, no. (%) | 1751 (57.8) |
| Body-mass index, kg/m2* | 24.7 ± 5.0 |
| ≤18 kg/m2, no. (%) | 128 (4.2) |
| ≥30 kg/m2, no. (%) | 405 (13.4) |
| Eastern Cooperative Oncology Group performance status, no. (%)† | |
| 0 | 1642 (58.1) |
| 1 | 930 (32.9) |
| 2 | 227 (8.0) |
| 3 | 28 (1.0) |
| 4 or 5 | 0 (0.0) |
| Medical history, no. (%)‡ | |
| Previous thromboembolism | 448 (14.8) |
| Pulmonary embolism | 42 (1.4) |
| Deep-vein thrombosis | 129 (4.3) |
| Superficial-vein thrombosis | 54 (1.8) |
| Myocardial infarction | 104 (3.4) |
| Acute lower-limb ischemia | 114 (3.8) |
| Stroke or transient ischemic attack | 81 (2.7) |
| Previous implanted port | 231 (7.6) |
| Diabetes | 346 (11.4) |
| Ongoing medications at the time of inclusion | |
| Immunosuppressive therapy | 19 (0.6) |
| Corticosteroids | 161 (5.3) |
| Statins | 515 (17.0) |
| Erythropoietin | 13 (0.4) |
| Hormone therapy§ | 57 (1.9) |
| Anticoagulant agents at prophylactic dose|| | 247 (8.1) |
| Antiplatelet agents | 458 (15.1) |